计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| G647768-5mg |
5mg |
期货 ![]() |
| |
| G647768-10mg |
10mg |
期货 ![]() |
| |
| G647768-25mg |
25mg |
期货 ![]() |
| |
| G647768-50mg |
50mg |
期货 ![]() |
| |
| G647768-100mg |
100mg |
期货 ![]() |
|
| 别名 | 葛兰素史克 4027 |
|---|---|
| 规格或纯度 | ≥98% |
| 英文名称 | GSK 4027 |
| 生化机理 | GSK 4027 是 PCAF / GCN5 溴化结构域的化学探针,在时间分辨荧光共振能量转移(TR-FRET)测定中,PCAF 的 pIC 50 为 7.4±0.11。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
GSK 4027 is a chemical probe for the PCAF / GCN5 bromodomain with an pIC 50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. In Vitro GSK 4027 is a PCAF/GCN5 bromodomain chemical probe. p300/CREB binding protein associated factor (PCAF/KAT2B) and general control nonderepressible 5 (GCN5/KAT2A) are multidomain proteins that have been implicated in retroviral infection, inflammation pathways, and cancer development. GSK 4027 also demonstrates potency toward BRD4 BD1 and BRD9 inTR-FRET assay with pIC 50 s of <4.3 and 5.1±0.08, respectively. The selectivity of GSK 4027 against the wider bromodomain family is assessed in the BROMOscan panel with pK i of 8.9 and 8.9 for PCAF and GCN5, respectively. GSK 4027 shows equipotent activity against PCAF and GCN5 with K i of 1.4 nM for both bromodomains. As expected due to the encouraging measured artificial membrane permeability (500 nm/s), treatment of HEK293 cells with GSK 4027 displace full length PCAF from histone H3.3 with little drop-off from the biochemical assay and a pIC 50 7.2 (IC 50 60 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:pIC50: 7.4±0.11 (PCAF) |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenylpiperidin-3-yl]amino]pyridazin-3-one |
| INCHI | 1S/C17H21BrN4O/c1-21-10-13(12-6-4-3-5-7-12)8-14(11-21)20-15-9-19-22(2)17(23)16(15)18/h3-7,9,13-14,20H,8,10-11H2,1-2H3/t13-,14+/m0/s1 |
| InChi Key | VZAFGXCWAWRULT-UONOGXRCSA-N |
| Smiles | CN1CC(CC(C1)NC2=C(C(=O)N(N=C2)C)Br)C3=CC=CC=C3 |
| Isomeric SMILES | CN1C[C@H](C[C@H](C1)NC2=C(C(=O)N(N=C2)C)Br)C3=CC=CC=C3 |
| PubChem CID | 126961735 |
| MeSH Entry Terms | 4-bromo-2-methyl-5-((1-methyl-5-phenylpiperidin-3-yl)amino)pyridazin-3(2H)-one;GSK4027;GSK4028 |
| 分子量 | 377.28 |
| 溶解性 | DMSO : 50 mg/mL (132.53 mM; Need ultrasonic) |
|---|---|
| 分子量 | 377.300 g/mol |
| XLogP3 | 2.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 376.09 Da |
| 单同位素质量Monoisotopic Mass | 376.09 Da |
| 拓扑极表面积Topological Polar Surface Area | 47.900 Ų |
| 重原子数Heavy Atom Count | 23 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 513.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |